• ViaCyte to Present at ISSCR International Symposium: Stem Cell Biology to New Therapies

    9 days ago - By San Diego Biotechnology

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ - ViaCyte, Inc., a privately-held clinical-stage regenerative medicine company, announced an upcoming presentation at From Stem Cell Biology to New Therapies, an ISSCR International Symposium being held in Toro......
    Read more ...

     

  • Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3

    9 days ago - By San Diego Biotechnology

    An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring. Halozyme (NASDAQ: HA......
    Read more ...

     

  • Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint

    9 days ago - By San Diego Biotechnology

    Development of PEGPH20 to be Discontinued Immediately -
    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ - Halozyme Therapeutics, Inc. today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a fir......
    Read more ...